[8-K] Neuropace, Inc. Reports Material Event

Rhea-AI Filing Summary

NeuroPace, Inc. reported that it issued a press release announcing its financial results for the fiscal quarter ended June 30, 2025. The press release is furnished as Exhibit 99.1 to this current report and is incorporated by reference into the filing. The company explicitly states that the information in Item 2.02, including the exhibit, is furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act nor incorporated by reference in filings under the Securities Act except by specific reference. No financial figures or earnings metrics are included in the text of this report.

Insights

Financial Analyst

TL;DR: The company furnished an earnings press release but provided no financial figures in the filing, limiting immediate investor assessment.

The filing notifies investors that a press release reporting results for the fiscal quarter ended June 30, 2025, has been furnished as Exhibit 99.1. Because the 8-K itself contains no financial tables or earnings metrics, there is insufficient information in this report to evaluate revenue, profit, margins, cash flow, or balance-sheet changes. The explicit statement that the material is "furnished" and not "filed" limits its automatic incorporation into other SEC filings. Investors must review the Exhibit 99.1 press release for substantive financial detail.

Corporate Governance Expert

TL;DR: The company followed standard disclosure practice by furnishing an earnings release and clarifying it is "furnished, not filed," which has legal and incorporation implications.

The report properly attaches the press release as Exhibit 99.1 and includes the boilerplate clarification that the Item 2.02 information is furnished rather than filed, which preserves certain liability and incorporation boundaries under the securities laws. This is a routine form of disclosure; the filing contains no governance actions, executive changes, or other corporate events beyond furnishing the earnings release.

0001528287false00015282872025-08-122025-08-12

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 12, 2025

NEUROPACE, INC.

(Exact name of registrant as specified in its charter)

Delaware (State or Other Jurisdiction of Incorporation)			001-40337 (Commission File Number)			22-3550230 (IRS Employer Identification No.)
455 N. Bernardo Avenue            Mountain View, CA (Address of principal executive offices)						94043 (Zip Code)

(650) 237-2700

Registrant's telephone number, including area code

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.001 par value per share

NPCE

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02    Results of Operations and Financial Condition.

On August 12, 2025, the Company issued a press release announcing its financial results for the fiscal quarter ended June 30, 2025. A copy of the press release, dated August 12, 2025, is furnished hereto as Exhibit 99.1 and is incorporated herein by reference.

The foregoing information in this Item 2.02 (including the exhibit hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

Item 9.01    Financial Statements and Exhibits.

(d)    Exhibits.

Exhibit No.						Description
99.1						Press Release, dated August 12, 2025
104						Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			NeuroPace, Inc.
Dated: August 12, 2025			By:			/s/ Patrick Williams
						Patrick Williams
						Chief Financial Officer